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Here, we investigated whether an anti-allergy drug, ter-
fenadine, a¡ects interleukin-4-modulated cytokine ex-
pression in peripheral T cells. Peripheral blood T cells
were ¢rst stimulated with recombinant interleukin-4
and then tested for modulation of the mRNA of a panel
of cytokines using the reverse transcription^polymerase
chain reaction followed by Southern blot analysis. It
was found that T cells constitutively expressed mRNA
speci¢c to T helper 1 cytokines (interleukin-2, interfer-
on-c, tumor necrosis factor-a), which was markedly
downregulated upon stimulation with interleukin-4,
whereas mRNA for T helper 2 cytokines such as inter-
leukins 4, 5, and 6 was induced in response to interleu-
kin-4. Interestingly, the interleukin-4-induced expression
of all T helper 2 cytokines examined was markedly
downregulated by terfenadine. AmongT helper 1 cyto-
kines, interleukin-4-mediated suppression of tumor ne-
crosis factor-a was not a¡ected by terfenadine, which,
however, markedly restored mRNA expression of inter-
feron-c or interleukin-2. Electrophoretic mobility shift
assays using [32P]-labeled synthetic oligonucleotides
encoding the consensus binding motif of activator pro-
tein-1 demonstrated that interleukin-4-induced bind-
ing of activator protein-1 composed of JunB was
interfered by terfenadine. This study indicates that ter-
fenadine, at least partially, interferes with interleukin-
4-activated signaling, leading to terfenadine antagonism
against the modulatory impact of interleukin-4 onTcell
cytokines. Key words: activator protein-1/JunB/terfenadine/
T helper 1/T helper 2. J Invest Dermatol 121:490 ^495, 2003
A
rapid increase in allergic skin disorders has recently
been observed with approximately one-third of pa-
tients attending dermatology clinics. Atopic derma-
titis, in particular, has currently been highlighted
due to long-lasting itchy rashes, which may a¡ect
the entire surface of the body. In respect to pathogenesis of atopic
skin disorders, there is belief that T helper (Th) 2-type immune
responses play a pathogenic role (Akdis et al, 2000). This hypoth-
esis may be supported by the observations that: (1) elevated serum
levels of IgE is frequently observed in patients (Akdis et al, 2000),
and (2) skin-in¢ltrating T cells predominantly produce Th2-type
cytokines such as interleukin (IL)-4 and IL-5 (Hamid et al, 1994).
Collectively, it might be possible to postulate that atopic skin dis-
orders are triggered by cytokine-driven signals derived fromTh2
cells, such as IL-4.
Terfenadine is an anti-allergic drug, which is a nonsedating
histamine H1 receptor antagonist (Woodward and Munro, 1982).
In addition to its potent antihistaminic e¡ects, it has been re-
ported that terfenadine induces selective inhibition of Th2-type
cytokine produced by human peripheral T cells in vitro upon sti-
mulation with theTcell receptor and using activation of costimu-
latory signal via CD28 (Munakata et al, 1999). Besides these
observations, little is known about how terfenadine a¡ects signal-
ing, which may be underlying those changes. To explore further
the suggestion that atopic skin disorders might be mediated by
Th2-type immunity, we undertook this study to explore further
the e¡ects of terfenadine on IL-4-modulated cytokine expression
on peripheral T cells.
Our results show that terfenadine, at least partially, antagonizes
IL-4 in the modulation of mRNA expression of Tcell cytokines.
In addition, terfenadine can antagonize IL-4-activated binding
of transcription factor, activator protein (AP)-1 bearing a JunB
component.
MATERIALS ANDMETHODS
Preparation of freshly isolated peripheral Tcells Blood samples were
obtained from healthy volunteers under a protocal approved by the
Institutional Review Board of Kin Ki University School of Medicine.
Accordingly, informed consent was obtained from each individual. To
¢rst isolate peripheral blood mononuclear cells, 20 to 30 mL of peripheral
blood collected from healthy volunteers was layered on top of 20 mL
density gradient solution (Ficoll-Paque; Amersham Pharmacia Biotech
AB, Uppsala, Sweden) and centrifuged. Subsequently, peripheral blood
mononuclear cells recovered from the interface were incubated with
magnetic beads coupled with monoclonal antibodies directed against
CD19 and CD14 (Dinabeads; both purchased from Dynal A.S., Oslo,
Norway). Cells unbound to the beads were ¢nally resuspended in
RPMI1640 medium supplemented with 10% human AB serum, 1% L-
glutamine and 1% antibiotics/anti-mycotics. Percent enrichment was
quantitated by £uorescence-activated cell sorter analysis using a panel of
antibodies (CD3, CD14, CD19), which revealed that approximately 95%
of the preparations were T cells.
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Cell stimulation T cells were ¢rst incubated with 20 nM terfenadine
(kindly provided byAventis S.A., Strasbourg, France) or left untreated for
30 min, and stimulated thereafter with 10 ng per mL recombinant human
IL-4 (R&D Systems, Minneapolis, Minnesota) or left unstimulated. For
some experiments, T cells were stimulated with histamine ranged at 10^5
to  M. Other anti-allergic drugs, ketotifen or promethazine (both
purchased from Sigma, St Louis, Missouri) were used as controls.
RNA extraction Terfenadine-pretreated cells were stimulated with 10
ng per mL recombinant IL-4 or left untreated, and harvested 3 h later.
RNA was extracted according to the acidic phenol procedure described
previously (Aragane et al, 1996). The amounts of RNA in samples were
determined photometrically at 260 nm and the RNA samples were
subjected to the reverse transcription^polymerase chain reaction (reverse
transcription^PCR).
Reverse transcription^PCR Five micrograms of total RNA was
reverse transcribed using dT17 (Takara, Tokyo, Japan). Semi-quantitative
reverse transcription^PCR ampli¢cation was conducted as described
elsewhere (Aragane et al, 1996). Brie£y, we ampli¢ed all cDNA samples
with primers speci¢c to b-actin using various cycle numbers and dilution
factors, and thereby determined the optimal concentration of each sample
and a cycle number showing a logarithmic increase in ampli¢cation.
Samples were then ampli¢ed using primers speci¢c for IL-2, IL-4, IL-5,
IL-6, tumor necrosis factor (TNF)-a, and interferon (IFN)-g, respectively.
All PCR primers used in this study were purchased from Clontech (Palo
Alto, California).
Southern blot analysis To monitor speci¢city of PCR signals,
Southern blot analysis was performed. Brie£y, PCR products were
fractionated in a 2% agarose gel and transferred on to nylon membranes
(Hybond; Amersham, Buckinghamshire, UK) by employing a capillary
blotting method. The membranes were then hybridized with [32P]-labeled
cDNA probes encoding IL-2, IL-4, IL-5, IL-6, IFN-g, and TNF-a,
respectively, in 5 sodium citrate/chloride bu¡er, 5Denhardt’s solution
(0.1% polyvinylpyrrolidone, 0.1% Ficoll 400, 0.1% bovine serum
albumin), 0.5% sodium dodecyl sulfate (all chemicals purchased from
Sigma) at 651C overnight. After washing in 2 SSC for 10 min twice at
room temperature, 2 SSC/1% sodium dodecyl sulfate for 30 min twice
and 0.1sodium citrate/chloride bu¡er for 30 min twice at room
temperature, the membranes were autoradiographed to X-ray ¢lms at
^801C. PCR signals on the Southern blot analysis were densitometrically
quantitated using a densitograph unit (Atto,Tokyo, Japan).
Nuclear protein extracts Fifteen minutes after stimulation, the cells
were collected in tubes and washed three times with chilled phosphate-
bu¡ered saline by centrifugation at 200 g, 41C for 5 min. Preparation of
nuclear extracts was performed essentially as described previously (Aragane
et al, 1997). Brie£y, cells were allowed to swell in a hypotonic bu¡er (10
mM HEPES (pH 7.8), 0.1 mM ethylenediamine tetraacetic acid, 10 mM
KCl, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl £uoride) for
15 min on ice. The samples were then mixed with Nonidet P-40 (Sigma)
to a ¢nal concentration of 0.25% and minifuged at 1,850g, 41C for 5 min.
After discarding the supernatants, the pellets were resuspended in
hypertonic bu¡er (20 mM HEPES (pH 7.9), 350 mM NaCl, 1 mM
dithiothreitol, 1 mM phenylmethylsulfonyl £uoride), and incubated on ice
for 15 min. Both fractions were stored at ^801C until being used. These
samples were used for electrophoretic mobility shift assays (EMSA) as
nuclear extracts.
EMSA Synthetic double-stranded oligonucleotides encoding the
consensus binding motif of AP-1 or signal transducer/activator of
transcription (STAT)-5 and -6 (STAT-5/6) were purchased from Santa
Cruz (Santa Cruz, CA). Binding reactions were performed with 5 mg of
protein, 5104 cpm of the [32P]-labeled double stranded oligonucleotides,
50 mM KCl, and 4 mg of poly(dI-dC) (Boehringer Mannheim,
Mannheim, Germany) for 25 min at room temperature. To monitor
speci¢city of the binding, nuclear protein fractions were preincubated
with an antibody directed against JunB (sc-73, Santa Cruz), c-Jun (Ab-1,
Oncogene, San Diego, CA), JunD (sc-74K, Santa Cruz), c-Fos (Ab-2,
Oncogene), or with nonimmune rabbit serum used as an irrelevant
control IgG. The anti-JunB recognizes the C-terminus of the protein,
which is crucial for the binding to the speci¢c DNA sequences (Ryder
et al, 1988). Therefore, according to a previous report, the addition of the
antibody to the reaction usually results in abrogation of the binding
(Yamazaki et al, 2002). Reaction mixture was applied to native high ionic
gels (1Tris/glycine bu¡er, 5% acrylamide (acrylamide/bis ratio, 19:1)) and
electrophoresis was performed at 100 V for 90 min; then the gels were dried
by a gel dryer and autoradiographed at ^801C.
Enzyme-linked immunosorbent assays (ELISA) To quantify
cytokines released from T cells, supernatants were collected 18 h after
stimulation and applied to ELISA speci¢c for various cytokines, including
IL-2, IL-5, IL-10, IL-13, TNF-a, and IFN-g. All ELISA systems were
purchased from R&D Systems.
RESULTS
Terfenadine suppresses histamine-induced production of
Th2 cytokines, IL-5 and IL-10 Terfenadine is a nonsedating
H1 receptor antagonist, and therefore should be able to block
biologic events induced by histamine. Therefore, we ¢rst
checked the e¡ects of terfenadine on histamine-induced
cytokine production. To do so, T cells were ¢rst preincubated
with or without 20 nM terfenadine for 30 min and then
stimulated with various concentrations of histamine.
Supernatants were collected 18 h later and production of IL-5
and IL-10, Th2 cytokines and TNF-a, a Th1 cytokine, were
tested using speci¢c ELISA systems. The production of both IL-
5 and IL-10 was signi¢cantly enhanced by histamine in a
concentration-dependent manner, whereas in the presence of
terfenadine histamine failed to upregulate the production
(Fig 1a,b). This indicates that histamine-induced production of
Th2 cytokines was counterregulated by terfenadine through
blockage of activation of histamine receptors. In contrast,
histamine did not a¡ect the constitutive production of TNF-a,
which was not further modulated by terfenadine (Fig 1c). It is
noteworthy that in the absence of histamine terfenadine was not
able to modify the constitutive production of IL-5, IL-10, or
TNF-a, indicating that contamination of endogenous histamine,
i.e., derived from serum or T cell preparation, if present, did not
play any part in the production of T cell cytokines tested. The
concentration of terfenadine used in this study (20 nM) turned
out to be nontoxic for T cells as viability of T cells was not
signi¢cantly a¡ected by this concentration of terfenadine as
measured by a trypan blue exclusion assay (Fig 1d). Based on
these observations, we used this concentration of terfenadine
(20 nM) throughout this study.
Terfenadine antagonized IL-4-modulated mRNA
expression of T cell cytokines As terfenadine is known to
improve the clinical symptoms of atopic skin disorders, in
which IL-4 plays a central part, we hypothesized that the
pharmacologic e¡ects of terfenadine are, in part attributed to its
antagonism against IL-4. To address this issue, we ¢rst tested IL-
4-induced modulation of Th2-type cytokines, including IL-4,
IL-5, and IL-6 in T cells. Therefore, PCR ampli¢cation using
primers of the respective cytokines was conducted, followed by
Southern blot analysis to con¢rm the speci¢city of the PCR
signals. Constitutive expression of mRNA speci¢c for these
Th2-type cytokines was markedly induced upon stimulation
with IL-4 (Fig 2a). The addition of 20 nM terfenadine alone to
T cells did not alter the mRNA expression of cytokines tested,
excluding the possibility that terfenadine itself a¡ects the
respective message in the absence of IL-4 (data not shown).
Interestingly, 20 nM terfenadine markedly prevented upregula-
tion of IL-4-induced mRNA expression for all Th2-type
cytokines tested. Together, these data indicate that terfenadine
suppressed IL-4-induced mRNA expression speci¢c for Th2
cytokines in T cells. We next focused on modulation of
Th1 cytokines in T cells by IL-4. As shown in Fig 2(a), consti-
tutive mRNA expression of Th1-speci¢c cytokines was
markedly downregulated by stimulation with IL-4. IL-4-
induced downregulation of TNF-a mRNA was not a¡ected
by terfenadine, which, however, markedly restored IL-4-
downregulated expression of IFN-g (Fig 2a). Furthermore,
downregulated expression of IL-2 mRNA was moderately
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restored by terfenadine (Fig 2). These data indicate that
terfenadine, at least partially, counteracts IL-4-induced modula-
tion of gene expression in respect to Th1 cytokines. The PCR
signals were quanti¢ed densitometrically as shown in Fig 2(b).
Collectively, terfenadine tends to antagonize IL-4-modulated
expression of T cell cytokines.
Modulations of IL-4-induced cytokine production by
terfenadine Based on the RNA data shown in the above, we
next checked modulation of IL-4-induced cytokine production
by terfenadine at the protein level. Therefore, we performed
ELISA assays speci¢c for various cytokines including IL-2, IL-5,
IL-10, IL-13, TNF-a, and IFN-g (Table I). To examine the
modulatory e¡ects characteristic of terfenadine, other anti-
allergic drugs, ketotifen and promethazine were used as controls,
both of which are well known H1R antagonists. For this
purpose, T cells were ¢rst preincubated with either 20 nM
terfenadine, 20 nM ketotifen, 20 nM promethazine, or left
unincubated. In the preliminary experiments, we added various
concentrations of either drug on freshly isolated T cells and
checked the viability. Viability of T cells were signi¢cantly
impaired (the viability o50%) when 10-fold higher con-
centration of each drug was added (data not shown). Thirty
minutes later, cells were stimulated with 10 ng per mL IL-4 or
left unstimulated, 18 h later supernatants were harvested, and
ELISA assays were performed. Con¢rming the RNA data
(Fig 2), ELISA assays revealed that constitutive production of
Th1 cytokines (IL-2, IFN-g, TNF-a) was suppressed by IL-4,
which induced the release of Th2 cytokines, such as IL-5, IL-10,
and IL-13 (Table I). Terfenadine downmodulated the IL-4-
enhanced production of Th2 cytokines (IL-5, IL-10, IL-13),
whereas it partially, but signi¢cantly restored IL-4-suppressed
Figure1. Terfenadine inhibited histamine-induced cytokine production from T cells. Peripheral T cells derived from healthy donors (n¼ 3) were
cultured in the presence or the absence of 20 nM terfenadine for 30 min, and either stimulated with various concentrations of histamine (0^10^5 M) or left
untreated. Eighteen hours later, culture supernatants were collected, and cytokines released to the supernatants were quanti¢ed using ELISA kits speci¢c for
IL-5 (a), IL-10 (b), and TNF-a (c). Note that this concentration of terfenadine used throughout this study was not toxic for T cells that were cultured in the
presence of 20 nM terfenadine for 18 h (d ). An asterisk in (d ) indicates a statistically signi¢cant decrease in viability of T cells when compared with those
cultured in the absence of terfenadine (0 nM). TFD; terfenadine.
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production of Th1 cytokines (IL-2, TNF-a), but failed to do so
for IFN-g (Table I). In contrast, ketotifen exerted such
modulatory e¡ects on TNF-a and IL-13, whereas promethazine
did so for TNF-a only (Table I).When T cells were treated with
the 10-fold lower concentration (2 nM) of ketotifen and
promethazine and then stimulated with 10 ng IL-4 per mL, the
production of TNF-a protein was 18.470.65 pg per mL and
16.371.01 pg per mL, respectively, both of which were not as
impressive as that observed with 20 nM of each drug (data not
shown). The terfenadine e¡ects on IL-4-downregulated
IFN-g and IL-4-downregulated-TNF-a protein release were
inconsistent with those seen at their mRNA levels (Fig 2).
Although the reason for this discrepancy is presently unknown,
it might be that terfenadine is able to post-transcriptionally
inhibit protein synthesis of TNF-a and the opposite is true for
IFN-g. This issue still remains unknown. Overall, however,
there is also a tendency that terfenadine antagonizes IL-4-
modulated production of T cell cytokines at protein levels.
Terfenadine interferes with IL-4-mediated activation of the
transcription factor, AP-1 To get further insight into the
e¡ect of terfenadine on IL-4-induced modulation of T cell
cytokines, we next focused on signaling events activated by IL-
4. To do so, a transcription factor, AP-1, was selected, and
EMSA were performed using [32P]-labeled synthetic
oligonucleotides encoding the consensus binding sequences for
AP-1 (Fig 3). It was found that AP-1 binding was activated
upon IL-4 stimulation, whereas in the presence of terfenadine
IL-4 failed to activate AP-1 binding (Fig 3). Furthermore, the
IL-4-induced AP-1 binding was prevented by preincubation
of the nuclear extracts with an antibody directed against JunB
(Fig 4), a component of AP-1 complex, whereas the binding
was not a¡ected by anti-c-Jun, anti-c-Fos, and anti-JunD.
Together, this indicates that the AP-1 complex activated by IL-4
is composed of the JunB component. To address whether
terfenadine a¡ects IL-4-activated transcription factors other than
AP-1, [32P]-labeled oligonucleotides encoding consensus binding
sites for STAT-5/6 were used, and EMSA performed (Fig 5).
STAT-6 is well known to be activated by IL-4. As initially
anticipated, IL-4 activated the binding of STAT-6, whereas
terfenadine failed to interfere with the IL-4-activated STAT-6
binding, indicating that terfenadine did not a¡ect the IL-4-
activated binding of STAT-6.
DISCUSSION
Terfenadine is a well-tolerated anti-allergy drug, whose therapeu-
tic spectra widely span various allergic disorders, including aller-
gic rhinitis, bronchial asthma, urticaria, and in£ammatory
skin conditions, such as eczemas and atopic dermatitis (Buckley
et al, 1985; Ra¡erty and Holgate, 1987; Hjorth, 1988). The results
presented in this paper support our initial hypothesis of ter-
fenadine-mediated antagonism against IL-4-modulated gene
expression of T cell cytokines. Here, we demonstrated that
IL-4-mediated modulation of transcripts of the T cell cytokines
tested, except forTNF-a, was counteracted by terfenadine. It pre-
viously has been shown that terfenadine inhibited the production
of Th2 cytokines (IL-4, IL-5), but not Th1 cytokines (IL-2, IFN-
g) from peripheral Tcells, which were stimulated via activation of
the T cell receptor and costimulatory signals or their equivalents
(see introductory paragraphs) (Munakata et al, 1999). In contrast,
we stimulated T cells with IL-4. Because di¡erent stimuli may
lead to activation of di¡erent signaling pathways, the results col-
lectively indicate that terfenadine not only prevents the produc-
tion of IL-4, but also antagonizes the biologic e¡ects of IL-4.
We next assessed how terfenadine antagonizes the biologic ac-
tivity of IL-4. Therefore, we focused on the transcription factor,
AP-1 (Liebermann et al, 1998). As the binding motif of AP-1
is rather ubiquitously distributed in the promoter regions of
Figure 2. Terfenadine modi¢ed IL-4-induced mRNA expression of
cytokines in peripheral T cells. (a) Peripheral T cells derived from
healthy donors (n¼ 5) were cultured in the presence or absence of 20 nM
terfenadine for 30 min, and either stimulated with 10 ng per mL recombi-
nant IL-4 or left untreated. Three hours later, the cells were harvested, total
cellular RNAwas extracted and reverse transcribed, and reverse transcrip-
tion^PCR analysis was performed using primers speci¢c for Th2-type cy-
tokines, including IL-4, IL-5, IL-6, or IL-2,TNF-a, IFN-g (Th1 cytokines)
as indicated. Subsequently, Southern blot analysis was performed as de-
scribed in Materials and Methods. Note that the addition of 20 nM terfena-
dine alone did not alter the basal expression of each cytokine nor of b-actin
(data not shown). (b) PCR signals were quanti¢ed densitometrically and
the fold induction was shown. To do so, a densitometric value of each
PCR signal was divided by that of b-actin at the respective time point,
and that of unstimulated cells of each cytokine was then scored as 1.
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numerous genes (Dendorfer, 1996), it might be possible that acti-
vation of AP-1 leads to deregulation of biologic events, such as
atopic dermatitis (Chan et al, 1996). Furthermore, we recently
showed that the binding of AP-1was markedly enhanced in pro-
teins extracted from IL-4-stimulated peripheral blood mononuc-
lear cells derived from patients with atopic dermatitis, when
compared with those from healthy individuals (Yamazaki et al
2002). Therefore, e¡ective antagonism of AP-1 activation may re-
sult in improvement of allergic diseases, in which overactivation
of AP-1might play a causative role.The EMSA using the consen-
sus binding motif of AP-1 revealed that terfenadine markedly
suppresses AP-1 binding induced by IL-4, suggesting that
terfenadine interferes with AP-1-mediated biologic phenomena.
Interestingly, IL-4-induced AP-1 binding was prevented by pre-
incubating nuclear proteins with an antibody directed against
JunB, but not with antibodies against c-Jun, c-Fos, and JunD, in-
dicating that the IL-4-activated AP-1 complex is composed of
the JunB protein. Currently, it has been reported that JunB may
be involved in IL-4 expression, thereby being able to direct Th2
di¡erentiation (Rincon et al, 1997; Li et al, 1999). In this context,
our results showing the downregulation of Th1 cytokines and
upregulation of Th2 cytokines, both of which are induced by
IL-4, favor the concept that IL-4 dictates the fate of T cells to
Th2 cells. Owing to the absence of antigen, antigen-presenting
cells and/or costimulatory signals in the culture condition, we
only can analyze terfenadine antagonism against IL-4-mediated
signaling, but not the e¡ect on T cell di¡erentiation into Th2
cells. It would be interesting to check whether di¡erentiation of
Th2 cells is inhibited by terfenadine or other anti-histamines.
This question is still open for further investigation.
Although suppression of IL-4-induced expression of Tcell cy-
tokines by terfenadine is clearly shown in this study, underlying
mechanisms remain largely unknown. It has currently been re-
ported that Th1 and Th2 preferentially express H1 receptor
(H1R) and H2R, respectively, and that histamine through the
binding to H1R induces di¡erentiation of Th1 cells ( Jutel et al,
Table I. Comparison of suppressive e¡ects of anti-histaminics on IL-4-modulated cytokine production
Control IL-4a IL-4þ TFDb IL-4þ KETc,d IL-4þ PMTe,f
IL-2g 109.375.85 31.370.97 59.673.90,h 29.672.44w,i 38.973.90w,j
IFNgg 48.376.42 18.676.10 20.673.21w,h 16.876.10w,i 19.275.05w,j
TNFag 69.5716.6 13.570.77 26.570.77,h 27.471.02,i 26.470.51,j
IL-5g 17.671.34 110.678.38 71.574.61,h 89.578.87w,i 104.9717.98w,j
IL-10g 19.670.60 45.875.56 23.970.75,h 36.772.55w,i 40.572.85w,j
IL-13g 474.5737.65 906.678.69 705.9772.41,h 700.8724.6,i 890.2743.44w,j
aT cells were stimulated with 10 ng/ml recombinant IL-4.
bT cells were preincubated for 30 minutes in the presence of 20 nM terfenadine and stimulated with IL-4.
cKET, ketotifen.
dT cells were preincubated for 30 minutes in the presence of 20 nM ketotifen and stimulated with IL-4.
ePMT, promethazine.
fT cells were preincubated for 30 minutes in the presence of 20 nM promethazine and stimulated with IL-4.
gSupernatants of Tcells cultured for 18 hours in the indicated culture condition were applied to ELISA assays for the respective cytokines. Each value is expressed pg/ml.
hPaired student-t tests were conducted between values of the respective cytokine produced fromT cells stimulated with IL-4 alone and with TFD plus IL-4.
iPaired student-t tests were conducted between values of the respective cytokine produced fromT cells stimulated with IL-4 alone and with KET plus IL-4.
jPaired student-t tests were conducted between values of the respective cytokine produced fromT cells stimulated with IL-4 alone and with PMT plus IL-4.
po0.05.
wNot signi¢cant.
Figure 3. Electrophoretic mobility shift assays. Peripheral T cells were
cultured in the presence or absence of 20 nM terfenadine for 30 min, and
either stimulated with 10 ng per mL IL-4 or left untreated. Fifteen minutes
later, the cells were harvested and nuclear protein fractions were prepared.
EMSAwas performed with 4 mg nuclear extracts using [32P]-labeled syn-
thetic oligonucleotides encoding the consensus binding sequences for AP-
1. The speci¢c binding of AP-1 is shown by the arrow.
Figure 4. JunB as a component of AP-1 complex. Antibody blocking
experiments were performed to characterize which nuclear proteins are ac-
tivated in this experimental system. Nuclear extracts were preincubated
with rabbit polyclonal antisera against JunB or an antibody directed against
c-Jun, c-Fos, or JunD, followed by the identical procedures to those de-
scribed in Fig 3.
Figure 5. IL-4-activated STAT-6 was not a¡ected by terfenadine.
Peripheral T cells were cultured in the presence or the absence of 20 nM
terfenadine for 30 min, and either stimulated with 10 ng per mL IL-4 or
left untreated. Fifteen minutes later, the cells were harvested and nuclear
protein fractions were prepared. EMSA was performed as in Fig 4 with
[32P]-labeled synthetic oligonucleotides encoding the consensus binding
sequences for S.
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2001). If terfenadine exclusively exerts the inhibitory e¡ects
through the binding to H1R in our experimental system, Th1
type cytokines should preferentially have been suppressed. Be-
cause we stimulated freshly isolated peripheral T cells with IL-4
alone and did not activate T cell receptor and costimulatory sig-
nals, T cells analyzed di¡ered from those in Jutel et al (2001). Be-
cause IL-4-induced expression of Th2 cytokines, however, was
clearly inhibited by terfenadine, the results imply that terfenadine
through binding to molecule(s) other than H1R might a¡ect IL-
4-signaling.We presently have no ¢rm idea how terfenadine an-
tagonizes IL-4-induced cytokine production, i.e., activation
of suppressive signals through the binding to H1R or other
molecules. In this respect, it is worthy to note that anti-allergic
drugs may bind to various molecules, including S100A1 and
S100B, inviting the speculation that anti-allergic drugs through
binding to these proteins might inhibit degranulation (Shishibori
et al, 1999; Okada et al, 2002). In the respective papers, it was de-
scribed that anti-allergic drugs may also bind to other molecules,
such as calcineurin a and b, 14 -3-3 proteins, neurocalcins and cal-
modulin. Although such detailed analysis of the binding proteins
of terfenadine has not been performed so far, it might be possible
to speculate that terfenadine through binding to surface mole-
cule(s) may interfere with IL-4 signaling. This issue still remains
to be elucidated. Furthermore, inTable I we have shown that ke-
totifen and promethazine, though less impressive than terfena-
dine, restored IL-4-suppressed production of TNF-a as well.
Although careful titration studies of these drugs were not con-
ducted on the e¡ects on IL-4-modulated expression of the cyto-
kines tested, such studies, by expanding the numbers of drugs to
be tested, might bring us further insights of how anti-allergic
drugs exert their immune modulatory properties.
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